Search results
Your search for Supportan returned no results
Showing 256 to 270 of 746 results for supported
Showing 256 to 270 of 746 results for supported
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)
Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)
Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.
Evidence standards framework (ESF) for digital health technologies
NICE standards for innovators of digital health technologies and NHS commissioners
Renal replacement therapy and conservative management (NG107)
This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.
Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)
Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
VEST external stent for coronary artery bypass grafts (MIB115)
NICE has developed a medtech innovation briefing (MIB) on the VEST external stent for coronary artery bypass grafts .
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Adalimumab for treating moderate to severe plaque psoriasis (TA146)
Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.